Skip to content Skip to footer
Subscribe Now
Thoughtspot_Saurabh Chaubey
THOUGHTSPOT

Reinventing Marketing Strategies for Biopharma Companies

Shots:  Conventional marketing strategies face challenges due to a lack of next-generation tools integrated into existing models.  Explore the nuances of biopharma marketing, highlighting its key elements and the advantages it offers.  Discover PharmaShots’ 4D model, which has been instrumental in shaping the biopharma marketing landscape.  Strategically crafted marketing plans are essential for long-term sustainability,…
January 22, 2025

Read more

Exclusive_Dr. Ikshit Sharma_2025
EXCLUSIVE

Exclusive Coverage: Dr. Ikshit Sharma from AIMIL Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots: Integrating innovation with the scientific principles of Ayurveda, AIMIL Pharmaceuticals caters to the growing needs of healthcare professionals, patients, and the animal healthcare sector PharmaShots welcomes Dr. Ikshit Sharma, Director at AIMIL Pharmaceuticals, in a riveting conversation. Ikshit stresses the significance of making investments in research and development for creating novel therapies and addressing…
January 20, 2025

Read more

Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at EADV Congress 2024: Uwe Gudat in a Stimulating Dialogue Exchange with PharmaShots

Shots:  At the European Academy of Dermatology and Venereology (EADV) 2024 Congress, Biocon Biologics presented results from two pivotal P-III clinical studies. These studies supported the interchangeability between Humira and adalimumab-fkjp, as well as the biosimilarity between Bmab 1200 and Stelara for the treatment of patients with moderate-to-severe plaque psoriasis  In an engaging conversation with…
January 6, 2025

Read more

New Drug Designations - November 2024
INSIGHTS+

New Drug Designations – November 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, and NMPA   The November 2024 report covers designations granted to 28 drugs and 3 devices, encompassing 9 small molecules, 6 biologics, 7 cell and gene therapies as well as 3 medical devices  Significant trends…
December 31, 2024

Read more

Viewpoints_Gerry Muhle
VIEWPOINTS

GAIN JPAC 2024: Gerry Muhle from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots:  GAIN JPAC is an emerging platform where leaders in aesthetics convene to share knowledge and advance patient treatment and safety  PharmaShots hosted Gerry Muhle, Head of Global Product Strategy at Galderma, who discussed the ‘Next by Galderma’ report, providing insights into the future of the aesthetics market and helping professionals better understand patient and…
December 30, 2024

Read more

Viewpoints_Jay Anders
VIEWPOINTS

Fostering Safe AI Use: Jay Anders from Medicomp in a Riveting Conversation with PharmaShots

Shots:  Nearly half of FDA-approved AI medical devices lack testing on real patient data, raising significant concerns about patient safety.  PharmaShots welcomes Jay Anders, CMO of Medicomp Systems, to discuss AI implementation trends in healthcare and strategies for ethical AI adoption by healthcare professionals.  Jay emphasizes the importance of clinical validations to ensure the safe…
December 23, 2024

Read more

Viewpoints_Mark Genovese 
VIEWPOINTS

Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

Shots:  Recently, at UEGW 2024, Lilly presented histologic and combined histologic-endoscopic outcomes from the VIVID-1 Phase III study, which evaluated the safety and efficacy of mirikizumab in adults with moderately to severely active Crohn’s disease  A key finding reported during UEG Week highlighted the interactions between mirikizumab and ustekinumab, particularly regarding histologic response and remission,…
December 18, 2024

Read more

Viewpoints_Harmony Garges
VIEWPOINTS

ViiV at IDWeek 2024: Dr. Harmony Garges in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Recently at IDWeek 2024, ViiV Healthcare presented data from two real-world studies on Apretude, a long-acting injectable (LAI) for HIV pre-exposure prophylaxis.  Dr. Harmony Garges, Chief Medical Officer at ViiV, shared insights from the presentations. The Opera cohort study found Apretude to be 99.7% effective in preventing HIV among participants. Additionally, the Trio Health…
December 16, 2024

Read more

Viewpoints_Dino Kazanis_James C. Swartz
VIEWPOINTS

Inspiring Innovations: Dino Kazanis and James Swartz in a Stimulating Conversation with PharmaShots

Shots:  Thermo Fisher Scientific has recently signed a distribution agreement with Labguru to accelerate research and drive scientific breakthroughs. This collaboration integrates Labguru’s state-of-the-art Electronic Lab Notebook (ELN) with Thermo Fisher Scientific’s comprehensive suite of Laboratory Information Management Systems (LIMS) and lab operations software solutions.  By combining ELN and LIMS tools, the partnership aims to…
December 11, 2024

Read more

CXO TALKS

CXO Talks: Cary Claiborne from Adial Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Welcome to the sixth episode of CXO Talks, featuring Cary Claiborne, CEO of Adial Pharmaceuticals a clinical-stage biopharmaceutical company dedicated to developing therapies for the treatment and prevention of addiction and related disorders.  Taking a walk down memory lane, Cary shares the inspiration behind founding Adial Pharmaceuticals. He recounts how an early study at the…
December 9, 2024

Read more

Load more